
Incyte forecasts downbeat annual sales of skin disease drug, shares fall
By Kamal Choudhury Bengaluru: Incyte Corp on Monday forecast annual sales of its skin disorder treatment Opzelura below Wall Street estimates, sending the drugmaker's shares down as much as 9per cent in afternoon trade. The company is banking on …